

**Gennex Laboratories Limited** 

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073. Telangana, INDIA Tel:+91-40-67334400 (30Lines), 23746451, Fax:+91-40-67334433 Email: info@gennexlab.com | www.gennexlab.com CIN:L24230TG1990PLCO11168

Ref: GLL/Board/2017-18/0041

To Dy. General Manager, **Bombay Stock Exchange Ltd.,** Phiroje Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Date: 14/02/2018.

To Asst. Manager (Listing) **The Ahmedabad Stock Exchange Ltd.,** Kamdhenu Complex, Opp.Sahajanand College, Ahmedabad – 380 015.

То

The Secretary **The Calcutta Stock Exchange Association Ltd.**, 7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject : Announcement of Un-audited financial results for the Third Quarter Ended December 31, 2017 together with the Limited Review Report of Auditors as Annexure – I.

Reference : Reg. 30(2) and Reg.33 of SEBI (LODR) Regulations, 2015.

This is to inform you that the Un-audited financial results for the Third Quarter Ended December 31, 2017 was approved and taken on record by the Board of Directors at their meeting held on February 14, 2018. The same was signed by Mr. Arihant Baid, Managing Director of the Company and we enclose Un-audited financial results for the Third Quarter Ended December 31, 2017 together with Limited Review Report as Annexure – I. We are arranging publication of the results in the newspaper and also in the website of the Company as required under Reg.33 read with 47 of SEBI (LODR) Regulations, 2015.

The Meeting commenced at 11.30 A.M. and concluded at. 12.30 P.M.

Kindly bring this to the notice of the members of the Exchange.

Thanking You,

Yours faithfully, For Gennex Laboratories Ltd.,

(1h Spend

**Authorised Signatory** 

Encl: as above



## **GENNEX LABORATORIES LIMITED**

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2017

PART I							(Rs. in lakhs)
Statemen	t of standalone Unaudited Results for the Quarter/Nine Months Ended 31/12/201	7					(Rs. in lakhs)
SI.		3 Months	Preceding	Corresponding 3	Year to date	Year to date	Previous
		ended	3 Months	Months ended	figures for	figures for the	year
			ended	in the previous	current period	previous	ended
				year	ended	year ended	
No.	Particulars	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
1	Income from Operations		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	(a) Revenue from Operations	1311.23	1157.90	1125.31	3306.58	3209.64	4348.61
		1311.23	1157.90	1125.31	3306.58	3209.64	4348.61
	(b) Other operating Income	12.82	2.65	6.22	17.65	12.02	11.89
	Total Income from operations (net)	1324.05	1160.55	1131.53	3324.23	3221.66	4360.50
	Total income from operations (net)	1324.05	1100.55	1131.33	3324.23	3221.00	4300.30
2	Expenses						
-	(a) Cost of material consumed	719.56	529.23	619.39	1793.31	1695.23	2356.98
	(b) Purchases of stock-in-trade	13.51	0.00	0.00	13.51	0.00	0.00
	(c) Changes in inventories of finished goods,		0.00	0.00			0.00
	work-in-progress and stock-in-trade	-3.50	99.54	-3.72	-56.23	81.31	35.71
	(d) Employee benefit expense	122.92	129.21	118.25	370.46	338.64	476.51
	(e) Excise Duty & GST on Sales	122.62	107.98	66.91	275.97	127.21	157.89
	(f) Finane Cost	15.23	19.66	7.72	49.44	41.40	70.54
	(g) Depreciation and amortisation expense	28.10	22.28	20.60	73.36	61.18	83.94
	(h) Other expenses	255.15	213.33	204.54	679.27	580.39	849.48
	Total expenses	1273.59	1121.23	1033.69	3199.09	2925.36	4031.05
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	50.46	39.32	97.84	125.14	296.30	329.45
4 5	Exceptional items	0.00	1.00	0	1.00	0 296.30	0
5 6	Profit(+)/Loss(-) before tax (3+4) Tax expense	50.46	40.32	97.84	126.14	296.30	329.45
Ū	(a) Current Tax						-40.00
	(b) Deferred tax(benefit/expense)						3.42
	(c) Taxes of earlier years	-19.60	0	0.85	-20.41	-3.07	-3.07
	Total Tax expense	-19.60	0.00	0.85	-20.41	-3.07	-39.65
7	Profit(+)/Loss(-) for the period from continuing operation (5-6)	30.86	40.32	98.69	105.73	293.23	289.80
8	Other comprehensive Income/(expense),net of tax expenses						
	Items that will not be reclassified subsequently to Profit or Loss						
	Income Tax relating to Items that will not be reclassified to Profit						
	or Loss	0	0.00	0.00	0.00	0.00	-19.37
	Total other comprehensive Income	0.00	0.00	0.00	0.00	0.00	-19.37
_							
9	Total comprehensive Income/(expense) for the period						
	(Comprising profit/(loss) and other Comprehensive Income for		40.00	00.00	405 70	000.00	070.40
	the period)	30.86	40.32	98.69	105.73	293.23	270.43
10	Paid-up Equity Share Capital						
	(Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
	(. ace tallet i.e. i odoli Equity endroj	1200.00	1200.00	1200.00	1200.00	1200.00	1200.00
11	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share)						
	( of Rs. 1 each ) (not annualised) :						
	(a) Basic	0.024	0.032	0.078	0.084	0.232	0.214
	(b) Diluted	0.024	0.032	0.078	0.084	0.232	0.214

NOTES to the results:

1) The above unaudited financial results for the nine month ended 31st December 2017 have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on February 14, 2018 and the limited review of the same has been carried out by the Auditors.

2) The Company has adopted Indian Accounting Standards (Ind AS) with effect from April 01,2017 as notified by the Ministry of Corporate Affair and accordingly the financial results for the quarter and year ended March 31,2017 are in compliance to the said standards. The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (as amended) prescribed under Section 133 of the Companies Act, 2015 read with the rule 3 of the Companies (Indian Accounting Standards) Rules,2015 and SEBI Circular No. CR/CFD/FAC/62/2016 DATED July 05,2016. Consequently, results for the nine month ended 31st December 2017 and 31 March 2017 have been restated/regrouped/re-casted to comply with Ind AS to make them comparable.

3) Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year.

4) Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.

5) The results pertaining to the relevant period of the previous year and year ended March,31,2017 stated in Ind AS format have not been subjeted to limited review or audit. However, the management has exercised neccessary due diligence to ensure the financial results provided a true and fair view of its affairs.

6) Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the nine month ended 31st December 2018 and vear ended 31 March 2017 is as follows:

and year ended 51 march 2017 is as follows.				(15.11110115)	
		Nine Month Ended			
Particulars	31.12.2017	31.12.2016	31.03.2017	31.03.2017	
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
Net profit reported for the nine month earlier as per the previous					
Indian GAAP	105.73	293.23	-22.80	270.43	
Re-measurement of acturial loss on defined benefit plan	0	0	0	19.37	
Net profit for the period as per Ind AS	105.73	293.23	-22.80	289.80	
Other Comprehensive Income					
Re-measurement of acturial loss on defined benefit plan	0	0	0	-19.37	
Total Comprehensive Income for the period as per Ind AS	105.73	293.23	-22.80	270.43	

7) The management has assessed the Identification of reportable segements in accordance with the requirement of the Ind AS 108

Operating Segment and believes that the Company has only one reporable segment namely " Bulk Drugs, Biotech Products and Intermediates".

For and on behalf of the Board For Gennex Laboratories Limited sd/-Arihant Baid Managing Director



## VINAY KARWA & ASSOCIATES CHARTERED ACCOUNTANTS

## LIMITED REVIEW REPORT

To The Board of Directors, GENNEX LABORATORIES LIMITED, Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of GENNEX LABORATORIES LIMITED for the Quarter ended 31<sup>th</sup> December, 2017 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we donot express an audit opinion.

Based on our review conducted as above and subject to the non presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 14/02/2018

